Project Grant R01CA297667
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $528K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- The National Cancer Institute awarded Vanderbilt University Medical Center $701,332 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate MRI cytometry as a noninvasive imaging biomarker for characterizing renal masses and distinguishing benign from malignant tumors. The project applies advanced diffusion MRI technique with multicompartment biophysical modeling to generate voxelwise maps of cell size and cellularity at...
- The National Cancer Institute awarded West Virginia University Research Corporation $484,944 under Project Grant R01CA316114 on June 2, 2026, to develop nano-encapsulated manganese oxide (NEMO) particles as a pH-sensitive MRI contrast agent for improved detection of residual breast cancer following neoadjuvant chemotherapy. The work falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project advances NEMO particle technology, which localizes to breast cancer...
- The National Cancer Institute awarded $694,929 to Vanderbilt University Medical Center on July 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to translate MR cytometry imaging into a clinical tool for cancer detection and diagnosis. MR cytometry is a diffusion MRI-based imaging technique that non-invasively measures mean cell size in vivo. The award funds an academic-industrial partnership among Vanderbilt University Medical Center, the University of Washington...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute awarded Emory University $639,077 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop rapid quantitative amide proton transfer-weighted (APTW) magnetic resonance imaging for brain tumor characterization at 3 Tesla field strength. The work addresses clinical challenges in chemical exchange saturation transfer (CEST) MRI by refining the quasi-steady-state (QUASS) algorithm to reconstruct equilibrium CEST signals...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....
- The National Cancer Institute awarded The Johns Hopkins University $591,419 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop low molecular weight theranostics targeting cluster of differentiation 38 (CD38) protein for multiple myeloma treatment and detection. The project focuses on two parallel therapeutic tools: an 18F-labeled positron emission tomography imaging agent for improved prognostication of multiple myeloma, and an actinium-225-based targeted...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute awarded The Trustees of the University of Pennsylvania $415,623 on April 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop metabolic imaging capabilities using hyperpolarized agents at tracer concentrations. The recipient will design and build a low-cost, continuous-flow device capable of producing highly polarized imaging agents suitable for continuous infusion into cell culture and small animal preclinical experiments....